Trial Profile
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Used for Future HIV Post-exposure Prophylaxis Regimens.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Darunavir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Acronyms PEP2
- 19 May 2021 Results examining penile distribution of Cobicistat/elvitegravir/emtricitabine/tenofovir-alafenamide and Darunavir by testing urethral and glans surface swabs collected following a single oral dose, published in the Journal of Antimicrobial Chemotherapy
- 26 Aug 2020 Status changed from recruiting to completed.
- 06 Feb 2019 Planned End Date changed from 15 Jan 2019 to 15 Dec 2019.